Researchers solve structure of key Ebola protein
The scientists describe their work in this week’s Early Edition of the Proceedings of the National Academy of Sciences. In the study, the team shows how the loss of the protein HMGB2, found in the surface layer of joint cartilage, leads to the progressive deterioration of the cartilage that is the hallmark of osteoarthritis. “We
Full Post: Discovery of cause of cartilage degeneration in osteoarthritis
Research led by Iowa State University scientists has them a step closer to finding a way to counter the Ebola virus.
A team led by Gaya Amarasinghe, an assistant professor in biochemistry, biophysics and molecular biology, has recently solved the structure from a key part of the Ebola protein known as VP35.
VP35 interferes with the natural resistance of host cells against viral infections.
“Usually when viruses infect cells, the host immune system can fight to eventually clear the virus. But with Ebola infections, the ability of the host to mount a defense against the invading virus is lost,” said Amarasinghe.
This is because the VP35 protein interferes with the host’s innate immune pathways that form the first line of defense against pathogens, he said.
In their research directed toward understanding host-viral interactions, Amarasinghe and his research team used a combination of X-ray crystallography and nucleic magnetic resonance spectroscopy to solve the structure using non-infectious protein samples.
A report describing the findings is published this week in the journal Proceedings of the National Academy of Sciences of the United States of America.
Now that the structure from a key part of VP35 is available, this information can be used as a template for anti-viral drug discovery.
“The next step is to use this structure to identify and design drugs that potentially bind with VP35,” he said.
If a drug that inhibits VP35 function can be discovered, then the Ebola virus could potentially be neutralized.
“Without functional VP35, the Ebola virus cannot replicate so it is noninfectious,” said Amarasinghe.
The Ebola virus can cause hemorrhagic fever that is usually fatal. According to the Center for Disease Control and Prevention, outbreaks have caused more than 1,000 deaths, mostly in Central Africa, since it was first recognized in 1976.
Bavituximab, an anti-viral drug developed by UT Southwestern Medical Center researchers, shows promise as a new strategy to fight viral diseases, including potential bioterrorism agents. In a study appearing in the December issue of Nature Medicine , groups of guinea pigs infected with a virus similar to Lassa fever virus recovered from the fatal disease
Full Post: Researchers develop new strategy for broad spectrum anti-viral drugs
Scientists report the discovery of a new species of Ebola virus, provisionally named Bundibugyo ebolavirus, November 21 in the open-access journal PLoS Pathogens. The virus, which was responsible for a hemorrhagic fever outbreak in western Uganda in 2007, has been characterized by a team of researchers from the Centers for Disease Control and Prevention in
Full Post: Discovery of new species of Ebola virus
Peregrine Pharmaceuticals, Inc. has announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number No. 7,455,833, which includes broad claims covering anti-viral applications of antibodies that directly bind to aminophospholipids. The aminophospholipid family of phospholipids, including phosphatidylserine (PS), represents a novel target for anti-viral therapies. The new patent follows publication this week
Full Post: Peregrine Pharmaceuticals awarded U.S. patent for anti-viral applications of phospholipid-targeting antibodies
Scientists at UT Southwestern Medical Center have determined that the immune-system protein interferon plays a key role in “teaching” the immune system how to fight off repeated infections of the same virus. The findings, available online and in the Dec. 15 issue of the Journal of Immunology, have potential application in the development of more
Full Post: Interferon needed for cells to ‘remember’ how to defeat a virus
A previously unknown regulatory step during human immunodeficiency (HIV) replication provides a potentially valuable new target for HIV/AIDS therapy, report researchers at the Salk Institute for Biological Studies and the University of Wisconsin, Madison. Their study, published in this week’s early online edition of the Public Library of Science, PLoS Pathogens, describes a new biological
Full Post: Previously unknown regulatory step during HIV replication provides potential new target for HIV/AIDS therapy